You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

131I-TM601

Showing 1 - 25 of 626
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma Trial in United States (131I-MIBG, Dinutuximab, Vorinostat)

Recruiting
  • Neuroblastoma
  • 131I-MIBG
  • +4 more
  • Los Angeles, California
  • +11 more
Jan 30, 2023

HER2-positive Breast Cancer Trial in Shanghai (68Ga/131I-SGMIB-5F7)

Not yet recruiting
  • HER2-positive Breast Cancer
  • 68Ga/131I-SGMIB-5F7
  • Shanghai, China
    Huashan Hospital
Aug 1, 2023

Ganglioneuroblastoma, Neuroblastoma Trial in Canada, Puerto Rico, United States (procedure, drug, biological, radiation)

Recruiting
  • Ganglioneuroblastoma
  • Neuroblastoma
  • Autologous Hematopoietic Stem Cell Transplantation
  • +18 more
  • Birmingham, Alabama
  • +158 more
Sep 14, 2022

Melanoma Trial in Clermont-Ferrand ([131I]ICF01012 (therapeutic dose level 1), [131I]ICF01012 (therapeutic dose level 2),

Recruiting
  • Melanoma
  • [131I]ICF01012 (therapeutic dose level 1)
  • +3 more
  • Clermont-Ferrand, France
  • +1 more
Jan 27, 2022

CNS/Leptomeningeal Tumors Trial in New York (131I-omburtamab)

Available
  • Central Nervous System/Leptomeningeal Neoplasms
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 15, 2022

Adolescent Idiopathic Scoliosis, Multimodal Analgesia, Opioid Induced Hyperalgesia Trial (Remifentanil TIVA, Dexmedetomidine

Not yet recruiting
  • Adolescent Idiopathic Scoliosis
  • +5 more
  • Remifentanil TIVA
  • +2 more
  • (no location specified)
Oct 19, 2023

Relapsed Neuroblastoma, Metastatic Pheochromocytoma Trial in Dallas (131 I-Metaiodobenzylguanidine, Potassium Iodide, G-csf)

No longer available
  • Relapsed Neuroblastoma
  • Metastatic Pheochromocytoma
  • 131 I-Metaiodobenzylguanidine
  • +2 more
  • Dallas, Texas
    The University of Texas Southwestern Medical Center
Apr 13, 2022

DIPG Trial (131I-Omburtamab, Convention Enhanced Delivery)

Not yet recruiting
  • DIPG
  • (no location specified)
Feb 7, 2022

Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme Trial (131I-IPA)

Not yet recruiting
  • Neoplastic Disease
  • +2 more
  • (no location specified)
Jul 6, 2022

Parkinson Disease Trial in Worldwide (IPX203 140 mg, IPX203 210 mg, IPX203 280 mg)

Completed
  • Parkinson Disease
  • IPX203 140 mg
  • +3 more
  • Phoenix, Arizona
  • +97 more
Apr 5, 2022

Neuroblastoma Trial in Canada, United States (131I-MIBG, Vincristine, Irinotecan)

Completed
Has Results
  • Neuroblastoma
  • 131I-MIBG
  • +3 more
  • Los Angeles, California
  • +13 more
May 16, 2022

Glioblastoma Multiforme Trial in Australia, Austria, Netherlands (4-L-[131I]iodo-phenylalanine (131I-IPA))

Active, not recruiting
  • Glioblastoma Multiforme
  • 4-L-[131I]iodo-phenylalanine (131I-IPA)
  • Gateshead, New South Wales, Australia
  • +4 more
Nov 25, 2021

Neuroblastoma, Neuroectodermal Tumors, Tumors Trial in United States (131I-MIBG, 131-MIBG + Vorinostat)

Recruiting
  • Neuroblastoma
  • +2 more
  • San Francisco, California
  • +15 more
Jan 7, 2022

Colorectal Tumors Trial in Heidelberg (Capecitabine, 131I-huA33 (131-Iodine on humanised mAb A33))

Completed
Has Results
  • Colorectal Neoplasms
  • Capecitabine
  • 131I-huA33 (131-Iodine on humanised monoclonal antibody A33)
  • Heidelberg, Victoria, Australia
    Ludwig Institute Oncology Unit and Tumor Targeting Program, Aust
Jan 11, 2022

Endocrine Disrupting Chemicals, Environmental Exposure, Health Literacy Trial in Berkeley (Mail-in Urine Test for EDCs)

Completed
  • Endocrine Disrupting Chemicals
  • +5 more
  • Mail-in Urine Test for EDCs
  • Berkeley, California
    Million Marker Wellness Inc.
Mar 22, 2023

Neuroblastoma, Pheochromocytoma Trial in New Hyde Park (131-I-meta-iodobenzylguanidine)

Available
  • Neuroblastoma
  • Pheochromocytoma
  • New Hyde Park, New York
    Cohen Children's Medical Center
Apr 4, 2022

Neuroblastoma, CNS Metastases, Leptomeningeal Metastases Trial in Worldwide (131I-omburtamab)

Recruiting
  • Neuroblastoma
  • +2 more
  • 131I-omburtamab
  • Los Angeles, California
  • +11 more
Dec 17, 2021

Intraoperative Blood Loss in Lumbar Spine Surgery

Completed
  • Blood Loss
  • Floseal
  • Baltimore, Maryland
    Johns Hopkins University School of Medicine
Apr 22, 2022

Prostate Cancer, Prostate Adenocarcinoma, Prostatic Tumors Trial in Montreal (131I-PSMA-1095 Radioligand Therapy (RLT))

Active, not recruiting
  • Prostate Cancer
  • +5 more
  • 131I-PSMA-1095 Radioligand Therapy (RLT)
  • Montreal, Quebec, Canada
    Stephan Probst
Oct 24, 2022

PostTraumatic Stress Disorder, Traumatic Brain Injury, Postconcussive Symptoms Trial in San Diego, Dallas (Active MeRT

Recruiting
  • PostTraumatic Stress Disorder
  • +2 more
  • Active MeRT Treatment
  • Sham MeRT Treatment
  • San Diego, California
  • +1 more
Sep 28, 2022

Salivary dysfuncTion After Radioiodine Treatment

Completed
  • Thyroid Cancer
  • Paris, France
    Pitié-Salpêtrière hospital
May 6, 2021

Epithelial Barrier Integrity in Biologic Treatment Response of

Not yet recruiting
  • Severe Eosinophilic Asthma w/wo CRSwNP
  • Mepolizumab 100 MG
  • Heraklion, Crete, Greece
    "PAGNI" University Hospital, Crete
May 3, 2022

Relapsed Neuroblastoma, Metastatic Pheochromocytoma Trial in Minneapolis (131 I-Metaiodobenzylguanidine (131I-MIBG), Potassium

Recruiting
  • Relapsed Neuroblastoma
  • Metastatic Pheochromocytoma
  • 131 I-Metaiodobenzylguanidine (131I-MIBG)
  • +3 more
  • Minneapolis, Minnesota
    University of Minnesota Masonic Cancer Center
Jan 20, 2022

Thyroid Cancer Trial in Bialystok (metformin, Radioactive iodine (I-131))

Not yet recruiting
  • Thyroid Cancer
  • Bialystok, Poland
    Department of Endocrinology, Diabetology and Internal Medicine,
Jul 26, 2022

Digestive Tumor Trial (TM4SF1-positive chimeric antigen receptor T-cell therapy)

Not yet recruiting
  • Digestive Tumor
  • TM4SF1-positive chimeric antigen receptor T-cell therapy
  • (no location specified)
Dec 21, 2022